You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)新冠中和抗體獲准開展II期臨床試驗
阿思達克 08-22 16:02
綠葉製藥(02186.HK)公布,附屬博安生物開發的創新型生物製品LY-CovMab已獲中國國家藥品監督管理局藥品審評中心准許開展II期臨床試驗。 LY-CovMab為博安生物開發的治療新型冠狀病毒肺炎「COVID -19」的單克隆中和抗體。同時,能夠抑制Delta和Lambda變異株的感染驗。 此前,LY-CovMab已被納入中國科技部《新型冠狀病毒中和抗體產品研發應急項目》,這將加速其於中國的研發上市進程。同時,該藥物也預期將在全球多個國家開展II期臨床試。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account